ÐÂÎÅÖÐÐÄ
News Center
bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾1ÀàÐÂÒ©±´ÄªËհݵ¥¿¹Ê×Åú·¢»õ
Ðû²¼Ê±¼ä£º2024-05-11
5ÔÂ11ÈÕ£¬£¬£¬£¬ £¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©±´ÄªËհݵ¥¿¹×¢ÉäÒº£¨ÉÌÆ·Ãû£º°²µÃÎÀ£©ÔÚÄϾ©½Äþ³§ÇøÍê³ÉÊ×Åú·¢»õ¡£¡£¡£¡£¡£ÄϾ©ÊнÄþ¸ßÐÂÇø¹Üί»áÖ÷ÈÎÁõ¹ã¸»¡¢¸±Ö÷ÈÎÅíÆô³¬£¬£¬£¬£¬ £¬£¬£¬Õý´óÌìÇ縱×ܲó»Գöϯ·¢»õÒÇʽ¡£¡£¡£¡£¡£
±´ÄªËհݵ¥¿¹×¢ÉäÒºÓÚ5ÔÂ9ÈÕ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÇ©·¢µÄ¡¶Ò©Æ·×¢²áÖ¤Êé¡·£¬£¬£¬£¬ £¬£¬£¬±»Åú׼͎áÑÎËá°²ÂÞÌæÄὺÄÒ¡¢¿¨²¬ºÍÒÀÍв´ÜÕÓÃÓÚÆÕ±éÆÚСϸ°û·Î°©£¨ES-SCLC£©µÄÒ»ÏßÖÎÁÆ¡£¡£¡£¡£¡£´ËÇ°£¬£¬£¬£¬ £¬£¬£¬¡¶CSCOСϸ°û·Î°©ÕïÁÆÖ¸ÄÏ¡·£¨2024£©ÍƼö±´ÄªËհݵ¥¿¹ÓÃÓÚES-SCLC»¼ÕßÍŽáÒ»ÏßÖÎÁÆ£¬£¬£¬£¬ £¬£¬£¬»¼Õß¿É»ñµÃ19.3¸öÔµÄÖÐλ×ÜÉúÑÄÆÚ£¬£¬£¬£¬ £¬£¬£¬ÊÇÏÖÔÚͬÀàÑо¿ÖÐ×î¸ßµÄÖÐλ×ÜÉúÑÄÆÚ[1,2]¡£¡£¡£¡£¡£
Áõ¹ã¸»¶ÔÕý´óÌìÇ籴ĪËհݵ¥¿¹µÄÀÖ³ÉÉÏÊС¢Ë³Ëì·¢»õ±í´ï×£ºØ¡£¡£¡£¡£¡£ËûÌåÏÖ£¬£¬£¬£¬ £¬£¬£¬Õý´óÌìÇçÊǺ£ÄÚÍ·²¿Ò½Ò©ÆóÒµÖ®Ò»£¬£¬£¬£¬ £¬£¬£¬Ñз¢Á¢Òì¼°Éú²úÄÜÁ¦ÒµÄÚÁìÏÈ¡£¡£¡£¡£¡£±´ÄªËհݵ¥¿¹×÷ΪÄϾ©ÊнñÄêÊ׸öÉÏÊеÄ1ÀàÁ¢ÒìÒ©£¬£¬£¬£¬ £¬£¬£¬ÊÇÒÔÆóҵΪÖ÷ÌåµÄ¶à·½ÅäºÏÆð¾¢µÄЧ¹û¡£¡£¡£¡£¡£Î´À´£¬£¬£¬£¬ £¬£¬£¬Õþ¸®½«ÖÂÁ¦ÓÚ´òÔìÈ«Ê¡ÁìÏȵÄÒ½Ò©±Õ»·Ð§ÀÍϵͳ£¬£¬£¬£¬ £¬£¬£¬ÓëÆóÒµÅäºÏÍƽø¿µ½¡ÊÂÒµÉú³¤¡£¡£¡£¡£¡£
15ʱ58·Ö£¬£¬£¬£¬ £¬£¬£¬ÂúÔØÒ©Æ·µÄÎïÁ÷³µ´ÓÕý´óÌìÇçÄϾ©½Äþ³§Çø³ö·¢£¬£¬£¬£¬ £¬£¬£¬½«²úÆ··¢ÍùÌìÏ¡£¡£¡£¡£¡£ÄϾ©ÊнÄþ¸ßÐÂÇø²¿·ÖÏòµ¼£¬£¬£¬£¬ £¬£¬£¬¹«Ë¾Ñз¢¡¢Éú²ú¡¢ÓªÏúϵͳÏà¹Ø²¿·ÖÈÏÕæÈËÅäºÏ¼ûÖ¤ÁËÕâÒ»Ö÷Ҫʱ¿Ì¡£¡£¡£¡£¡£
±´ÄªËհݵ¥¿¹ÊÇÈËÔ´»¯PD-L1µ¥¿Ë¡¿¹Ì壬£¬£¬£¬ £¬£¬£¬¿É×èÖ¹PD-L1ÓëTϸ°ûÍâòµÄPD-1ºÍB7.1ÊÜÌåÍŽᣬ£¬£¬£¬ £¬£¬£¬Ê¹Tϸ°û»Ö¸´ÉúÐÔ£¬£¬£¬£¬ £¬£¬£¬´Ó¶øÔöÇ¿ÃâÒßÓ¦´ð£¬£¬£¬£¬ £¬£¬£¬¾ßÓÐÖÎÁƶàÖÖÀàÐÍÖ×ÁöµÄDZÁ¦¡£¡£¡£¡£¡£¹¤ÒÕ·½Ã棬£¬£¬£¬ £¬£¬£¬±´ÄªËհݵ¥¿¹·Ö×ÓÉè¼Æ Fc ÇøÒýÈëÁËÌض¨µÄ°±»ùËáÍ»±äÍù¸´³ý¿¹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾ÐÔ×÷ÓÃ(ADCC) ºÍ²¹ÌåÒÀÀµÏ¸°û¶¾ÐÔ×÷Ó㨠CDC£©£¬£¬£¬£¬ £¬£¬£¬×î´óÏ޶ȵØÊͷű´ÄªËհݵ¥¿¹µÄ¿¹Ö×Áö»îÐÔ¡£¡£¡£¡£¡£
±¾´Î±´ÄªËհݵ¥¿¹Íê³ÉÊ×Åú·¢»õ£¬£¬£¬£¬ £¬£¬£¬½«Îª¿í´óES-SCLC»¼ÕßÌṩеÄÓÃÒ©Ñ¡Ôñ¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬ £¬£¬£¬Õý´óÌìÇç½üÆÚÒÑÏò¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©Ìá½»ÁËÑÎËá°²ÂÞÌæÄὺÄҺͱ´ÄªËհݵ¥¿¹×¢ÉäÒºÐÂ˳Ӧ֢µÄÉÏÊÐÉêÇ룬£¬£¬£¬ £¬£¬£¬²¢»ñµÃÊÜÀí£¬£¬£¬£¬ £¬£¬£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýÒ»¡¢¶þÏß»¯ÁƼƻ®ÖÎÁÆʧ°Ü»ò²»¿ÉÄÍÊܵķÇ΢ÎÀÐǸ߶Ȳ»Îȹ̣¨·ÇMSI-H£©»ò·ÇDNA´íÅäÐÞ¸´È±ÏÝ£¨·ÇdMMR£©µÄ¸´·¢ÐÔ»òתÒÆÐÔ×Ó¹¬ÄÚĤ°©¡£¡£¡£¡£¡£¸ü¶à±´ÄªËհݵ¥¿¹µÄÁÙ´²Ó¦Óÿª·¢ÕýÔÚÒ»Á¬ÍƽøÖУ¬£¬£¬£¬ £¬£¬£¬ÏÖÔÚ¶àÏîÁÙ´²¢óÆÚÊÔÑéÕýÔÚ¿ªÕ¹£¬£¬£¬£¬ £¬£¬£¬°üÀ¨Ò»ÏßÉö°©¡¢Ò»Ïß·ÇСϸ°û·Î°©¡¢·ÇСϸ°û·Î°©·Å»¯Áƺóά³ÖµÈ£¬£¬£¬£¬ £¬£¬£¬Î´À´½«½øÒ»²½¸»ºñ¼¯ÍÅÔÚÖ×ÁöÁìÓòµÄ²úÆ·¹ÜÏߣ¬£¬£¬£¬ £¬£¬£¬Ô츣¸ü¶à»¼Õß¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1. Cheng Y, Yang R, Chen J, et al. Benmelstobart with anlotinib plus chemotherapy as first-line therapy for ES-SCLC: a randomized, double-blind, phase III trial (ETER701). Presented at: 2023 World Lung Cancer Conference; September 9-12, 2023; Singapore, Republic of Singapore. OA01.03.
2. Benmelstobart Ups ES-SCLC Survival. Cancer Discov. 2023 Nov 1;13(11): 2296-2297.
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬ £¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬ £¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬ £¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬ £¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬ £¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬ £¬£¬£¬°üÀ¨Óйء¾±´ÄªËհݵ¥¿¹×¢ÉäÒº¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬ £¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬ £¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬ £¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬ £¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬ £¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬ £¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬ £¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£
ÄÚÈÝȪԴ£ºÕý´óÌìÇçÒ©Òµ¼¯ÍŹ«ÖÚºÅ